Statins and the risk of bleeding in patients taking dabigatran

Bo Lin Ho, Ya Ju Lin, Sheng Feng Lin, Ping Song Chou, Chien Fu Chen, Ruey Tay Lin, Han Hwa Hu, A. Ching Chao

研究成果: 雜誌貢獻文章同行評審

9 引文 斯高帕斯(Scopus)

摘要

Objectives: Dabigatran etexilate is a direct thrombin inhibitor that clinicians increasingly prescribe to prevent stroke in patients with non-valvular atrial fibrillation (NVAF). Clinicians also commonly prescribe statins for primary and secondary prevention of cardiovascular diseases. Little is known about the bleeding risk in patients taking a statin and dabigatran together. The aim of this study was to evaluate the safety and persistence of dabigatran after co-medication with statins. Materials and Methods: We performed a prospective, multicenter registry study of stroke patients with NVAF who initiated dabigatran therapy within 3 months after a clinically evident ischemic cerebrovascular event between 2013 and 2017. The main outcome measure was symptomatic bleeding after 90, 180, and 360 days. Results: In total, 652 patients (336 statin users, 316 non-users) were followed for 1 year after dabigatran therapy. Cox multivariate analysis demonstrated that male sex, prior use of aspirin, and concurrent use of an antiarrhythmic drug were associated with a higher risk of bleeding at 360 days. After adjusting time-dependent covariates, statin users had a significantly lower bleeding risk (adjusted hazard ratio: 0.11, P < 0.001) than non-users. Kaplan-Meier analysis indicated that patients prescribed with statins had a higher rate of bleeding-free survival (P = 0.028). Conclusion: For secondary prevention of stroke in patients with NVAF who are taking dabigatran etexilate, co-prescription with a statin was associated with a lower risk of bleeding complications. Future research is needed to determine the pharmacological mechanism underlying this effect.

原文英語
頁(從 - 到)455-461
頁數7
期刊Acta Neurologica Scandinavica
139
發行號5
DOIs
出版狀態已發佈 - 5月 1 2019

ASJC Scopus subject areas

  • 神經病學(臨床)
  • 神經內科

指紋

深入研究「Statins and the risk of bleeding in patients taking dabigatran」主題。共同形成了獨特的指紋。

引用此